Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

NR4A2 (Nuclear Receptor Subfamily 4, Group A, Member 2)

  • Floriana VolpicelliEmail author
  • Umberto di Porzio
  • Luca Colucci-D’Amato
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101617


Historical Background

Orphan nuclear receptor Nurr1, also known as nuclear receptor subfamily 4, group A, member 2 (NR4A2), together with Nur77 (NR4A1) and Nor1 (NR4A3), is a member of the steroid/thyroid hormone nuclear receptor superfamily. Unlike the other nuclear receptors, Nurr1 is an immediate early gene, and its transcription can be induced by various stimuli such as depolarization, cAMP, inflammation, hormones, calcium, and growth factors (Volpicelli et al. 2004). Structurally, Nurr1 lacks a hydrophobic pocket for ligand binding and might function as ligand-independent nuclear receptor (Wang et al. 2016)....

This is a preview of subscription content, log in to check access.


  1. Barneda-Zahonero B, Servitja JM, Badiola N, Miñano-Molina AJ, Fadó R, Saura CA, et al. Nurr1 protein is required for N-methyl-d-aspartic acid (NMDA) receptor-mediated neuronal survival. J Biol Chem. 2012;287:11351–62. doi:10.1074/jbc.M111.272427.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67:715–25. doi:10.1002/ana.21995.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Björklund A. α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med. 2012;4:163ra156. doi:10.1126/scitranslmed.3004676.CrossRefPubMedGoogle Scholar
  4. Decressac M, Volakakis N, Björklund A, Perlmann T. NURR1 in Parkinson disease – from pathogenesis to therapeutic potential. Nat Rev Neurol. 2013;9:629–36. doi:10.1038/nrneurol.2013.209.CrossRefPubMedGoogle Scholar
  5. Heng X, Jin G, Zhang X, Yang D, Zhu M, Shijun F, et al. Nurr1 regulates Top IIβ and functions in axon genesis of mesencephalic dopaminergic neurons. Mol Neurodegener. 2012;7:4. doi:10.1186/1750-1326-7-4.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Kim CH, Han BS, Moon J, Kim DJ, Shin J, Rajan S, et al. Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease. Proc Natl Acad Sci. 2015;112:8756–61. doi:10.1073/pnas.1509742112.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Liu H, Wei L, Tao Q, Deng H, Ming M, Xu P, et al. Decreased NURR1 and PITX3 gene expression in Chinese patients with Parkinson’s disease. Eur J Neurol. 2012;19:870–5. doi:10.1111/j.1468-1331.2011.03644.CrossRefPubMedGoogle Scholar
  8. McCoy JM, Walkenhorst DE, McCauley KS, Elaasar H, Everett JR, Mix KS. Orphan nuclear receptor NR4A2 induces transcription of the immunomodulatory peptide hormone prolactin. J Inflamm (Lond). 2015;12:13. doi:10.1186/s12950-015-0059-2.CrossRefGoogle Scholar
  9. Murphy EP, McEvoy A, Conneely OM, Bresnihan B, FitzGerald O. Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum. 2001;44:782–93.CrossRefPubMedGoogle Scholar
  10. Ranhotra HS. The NR4A orphan nuclear receptors: mediators in metabolism and diseases. J Recept Signal Transduct Res. 2015;35:184–8. doi:10.3109/10799893.2014.948555.CrossRefPubMedGoogle Scholar
  11. Raveney BJ, Oki S, Yamamura T. Nuclear receptor NR4A2 orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 signalling. PLoS One. 2013;8:e56595. doi:10.1371/journal.pone.0056595.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Safe S, Jin UH, Morpurgo B, Abudayyeh A, Singh M, Tjalkens RB. Nuclear receptor 4A (NR4A) family – orphans no more. J Steroid Biochem Mol Biol. 2016;157:48–60.CrossRefPubMedGoogle Scholar
  13. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009;137:47–59. doi:10.1016/j.cell.2009.01.038.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet. 2015;31:140–9.PubMedCrossRefGoogle Scholar
  15. Volpicelli F, Perrone-Capano C, Da Pozzo P, Colucci-D’Amato L, di Porzio U. Modulation of nurr1 gene expression in mesencephalic dopaminergic neurones. J Neurochem. 2004;88:1283–94. Erratum in: J Neurochem. 2004;90:256.PubMedCrossRefGoogle Scholar
  16. Volpicelli F, Caiazzo M, Greco D, Consales C, Leone L, Perrone-Capano C, et al. Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro. J Neurochem. 2007;102(2):441–53.CrossRefPubMedGoogle Scholar
  17. Volpicelli F, De Gregorio R, Pulcrano S, Perrone-Capano C, di Porzio U, Bellenchi GC. Direct regulation of Pitx3 expression by Nurr1 in culture and in developing mouse midbrain. PLoS One. 2012;7:e30661. doi:10.1371/journal.pone.0030661.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Wang J, Bi W, Zhao W, Varghese M, Koch RJ, Walker RH, et al. Selective brain penetrable Nurr1 transactivator for treating Parkinson’s disease. Oncotarget. 2016;7:7469–79. doi:10.18632/oncotarget.7191.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Wenzl K, Troppan K, Neumeister P, Deutsch AJ. The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms. Curr Drug Targets. 2015;16:38–46.CrossRefPubMedGoogle Scholar
  20. Zetterström RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science. 1997;276:248–50.CrossRefPubMedGoogle Scholar
  21. Zheng K, Heydari B, Simon DK. A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch Neurol. 2003;60:722–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Floriana Volpicelli
    • 1
    • 2
    Email author
  • Umberto di Porzio
    • 1
  • Luca Colucci-D’Amato
    • 3
    • 4
  1. 1.Institute of Genetics and Biophysics “Adriano Buzzati Traverso”, CNRNaplesItaly
  2. 2.Department of PharmacyUniversity of Naples Federico IINaplesItaly
  3. 3.Laboratory of Molecular and Cellular Pathology, Department of Environmental, Biological and Pharmaceutical Sciences and TechnologiesUniversity of Campania “L. Vanvitelli”CasertaItaly
  4. 4.Dipartimento di Scienze della VitaSeconda Università di NapoliCasertaItaly